Abstract: This review describes some of the most recent advances in the development and application of new technologies for detecting and managing glaucoma, including imaging, visual function testing, and tonometry. The widespread availability of mobile technology in the developing world is improving health care delivery, for example, with smartphones and mobile applications that allow patient data to be assessed remotely by health care providers.
G laucoma is an age-related chronic optic neuropathy and the leading cause of irreversible blindness worldwide. By 2020 glaucoma will be responsible for visual impairment of 4.5 million people, with differences among the diverse world regions. 1 Further predictions report that in 2040 the number of people with glaucoma worldwide will reach almost 112 million, disproportionally affecting Asian and African countries. 2 Facing an increasing burden of glaucoma, particularly in the developing world, the need for efficient glaucoma detection and management cannot be overemphasized.
A major challenge to try to tackle glaucoma-related blindness is to identify those with this eye disease before they become symptomatic (ie, with very advanced disease).
Conventional population-based screening for open-angle glaucoma (OAG) is not feasible or a good use of limited health resources, 3, 4 in part due to the lack of a simple and precise test to diagnose glaucoma satisfactorily. In low-to-middle-income countries (LMIC) with many deficiencies in public health interventions, the possibility of combined programs to address visual disorders may make sense, especially considering that some conditions such as glaucoma and cataract may often coexist. This review describes some of the most recent advances in the development and application of new technologies for detecting glaucoma. We will not cover technologies to detect angle-closure disease mainly because there is uncertainty whether primary angle-closure suspects [ie, narrow angles with normal intraocular pressure (IOP) and healthy optic discs] require any treatment at all. People with significant angle-closure disease (with increased IOP or glaucomatous damage) can be detected with the same techniques that are used to detect OAG.
Glaucoma is diagnosed clinically by detecting the characteristic changes of the optic disc and can be confirmed with the presence of a corresponding visual field (VF) defect. However, clinical diagnosis of glaucoma is subjective and relies on the examiner's experience. A particular challenge for detecting glaucoma is the wide variation of optic disc structure and size in the population. Therefore, there is an urgent need for novel and accurate techniques to detect glaucoma that can be used in different settings. In this article we will review promising new diagnostic technologies for glaucoma.
We are witnessing new practical applications of artificial intelligence (AI), including advances in the field of complex artificial neural networks (ANNs) and constant innovations in daily-used devices such as smartphones, laptops, electronic tablets, wireless communications, ect. The widespread availability of mobile technology in the developing world is improving health care delivery (eg, smartphones and mobile applications now allow patients to connect remotely with health care providers and to monitor their own health). 5, 6 Another aspect addressed in this review is the possibility of delivering glaucoma care using telemedicine, or teleglaucoma, that can be particularly useful for remote and underprovided populations. 7 
DIAGNOSTIC AND MONITORING TESTS Tonometry
There are several well-recognized risk factors for glaucoma, including elevated IOP, older age, ethnicity, and family history of glaucoma. Of all risk factors the level of IOP is the most important one and is the only one that can be modified with treatment. The risk of developing glaucoma rises with increasing IOP. This is supported by the fact that those patients presenting with advanced disease at diagnosis are more likely to have higher IOP. Higher IOP is also a risk factor for disease progression.
However, tonometry alone has poor accuracy to be considered a possible test for glaucoma screening or diagnosis because population studies have consistently found that many people with glaucoma have an IOP within "normal" levels and many people with high IOP do not have glaucoma. Several studies have described the prevalence of glaucoma according to IOP levels. 4 In the Baltimore Eye Survey the risk of having glaucoma in people with IOP greater than 26 mm Hg was 13 times higher than those with lower IOP.
Goldmann applanation tonometry (GAT) is currently the most commonly used tonometer by clinicians and GAT is accepted as the current reference standard. However, there are several limitations associated with GAT such as the skills required for its interpretation and the potential risk for corneal infection. 9 Applanation tonometry is based on the Imbert-Fick law, in which the force required to flatten the anterior corneal surface is equal to the true IOP times the flattened area at the posterior corneal surface. The fact is, although the flattened area of the anterior surface of the cornea is constant, the central corneal thickness, the corneal rigidity, and its resistance to a deforming force vary among eyes and individuals. The tear film can also influence IOP readings with GAT as the surface tension attracts the tonometer to the cornea, cancelling or reducing the force needed to flatten the cornea, but the precise influence of the tear film on IOP measurements is not fully understood. Some tonometers (eg, ocular response analyzer and dynamic contour tonometry) are designed to adjust for the patient's central corneal thickness.
In recent years a variety of tonometers have been introduced. However, current evidence indicates that there is substantial disagreement between alternative tonometers and GAT. 10 Self-monitoring of chronic diseases, such as monitoring blood glucose levels for diabetes mellitus and measuring blood pressure in hypertensive patients, can be effective for informing patients when their current treatment is not sufficiently effective, thereby providing them with a sense of control over their condition along with improved disease control. Having the ability to measure IOP at home throughout different periods in the day will enable physicians to identify potential failures in treatment and possibly improve the prognosis for the patient. The selfmonitoring approach could bring significant benefits to patients such as symptom management and an improved quality of life. Peak IOP and IOP fluctuations have been identified as risk factors for the development and progression of glaucoma. Diurnal fluctuations of IOP are highly unlikely to be observed during clinical visits. The Icare home tonometer (https://www.icaretonometer. com/products/icare-home-tonometer/) is based on the principle of rebound tonometry. No topical anesthetic is required, and there is minimal risk of corneal injury. It may be an option for some glaucoma patients to better monitor their IOP at home and aid in the management of their condition. [11] [12] [13] New technologies, such as sensors and wireless devices, present as promising tools that enable continuous monitoring of IOP.
14 Implantable sensors have revolutionized diagnosis and management of a wide range of diseases, including the fields of neurological diseases and neurorehabilitation. [15] [16] [17] Sensors have significant advantages in monitoring some conditions that would benefit undoubtedly from multiple real-life data, which is the case of diabetes and arterial hypertension. 18 By means of wearable sensors, biochemical and physiological information can be transmitted from home to remote sites. Combined with new technologies (Bluetooth, USB port, smartphones, ZigBee, Wifi connection, or even the Internet) or via telemetry, sensors can communicate to a cell phone or to an automated analytic system, sending parameters such as glycemia and even examination results such as heart rate, weight, or blood pressure. 19 This concept is known as mobile health or wireless health. 15, 20, 21 In fact, a wide range of sensor technologies have been employed to assess IOP. These sensors vary from strain-gauge sensors, capacitive type sensors, piezo-resistive sensors, etc.
14 Advances in technology are improving robustness and sensitivity of these sensor platforms. In particular, the use of silicon micromachining has made it feasible to integrate interface electronics into the devices, reducing their size and leading to large-scale production. 14 One of the first platforms used was the SENSIMED Triggerfish contact lens sensor (Sensimed AG, Lausanne, Switzerland). 22, 23 This soft silicone contact lens is provided with a circumferential sensor that consists of 2 platinum-titanium strain gauges designed to measure changes in the radius of curvature of the cornea. 24 A microprocessor transmits an output signal to a wireless antenna on the periocular surface. The data are transferred by a cable wire to an external portable recorder. The SENSIMED Triggerfish is noninvasive, but the clinical value of the data is uncertain.
The Eyemate-IO intraocular version (Implandata Ophthalmic Products, Hanover, Germany) is designed for ciliary sulcus placement during cataract surgery. 25, 26 It consists of a permanent implantable microsensor that is placed in front of the artificial intraocular lens, posterior to the iris. The device has been well tolerated, with no severe complications, yet it may be challenging in cases with narrow pupils. 25, 26 The device is available initially for primary implantation in patients with primary OAG undergoing cataract surgery. Implandata is also working on other versions to be used in other glaucoma conditions or even in patients undergoing corneal transplantation. The Eyemate-EO extraocular version is designed for suprachoroidal placement during nonpenetrating glaucoma surgery. 27 Both models depend on an external handheld device to charge the internal unit and extract data. Measured data are sent via that reader to a cloud-based database that allows remote access by the ophthalmologist. 28 In addition, a smartphone application allows the patient to view the pressure profile, to track the pressure history, and also to communicate with the doctor.
Recently, Mariacher et al 29 showed promising experimental results with an episcleral telemetric pressure transducer, which does not need intracameral or suprachoroidal surgery. Other sensors are those based on nanotechnology, including intraocular miniature flexible implantable sensors and noninvasive nanostructured sensing contact lenses. 30 It is likely that in the near future, new low-cost portable sensors will provide rapid feedback on IOP from accumulated sensor data collected over weeks to clinicians which will reduce their visits to clinic sites. Adaptations to smartphones can enable patients to automatically record their IOP and transmit the data by graphs and text over clinicians' smartphones or computers.
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Fundal Imaging
Assessment of the damaged optic nerve and retinal nerve fiber layer is a key method to detect glaucoma. 31 Stereoscopic fundus examination by an expert clinician is considered standard practice.
Automated imaging systems, particularly optical coherence tomography (OCT), are now widely used for glaucoma diagnosis (Figs. 1, 2). However, OCT examinations involve high costs which may not be affordable by some health care providers.
Optical coherence tomography is used to quantify the retinal thickness in areas that are relevant to the glaucomatous process, either close to the optic disc or at the macula (Fig. 3) . A metaanalysis evaluating diagnostic accuracy of OCT for glaucoma found that parameters for the circumpapillary retinal nerve fiber and communication capabilities, 21 and they have been developed as an inexpensive retinal photography tool. 34, 35 One example of a successful combination of fundal imaging and smartphone technology is the Portable Eye Examination Kit (PEEK) Retina (Peek Vision, London, United Kingdom), a smartphone camera adapter developed by Bastawrous et al. 36 This portable mobile phone retinal imaging system is of low cost and easy to use for minimally trained users. The PEEK Retina is capable of capturing excellent-quality optic disc and retinal images and has recently been validated for optic nerve imaging in populationbased studies in the developing world.
Multiple other adapters have been developed to convert modern smartphone cameras into fundus and anterior segment cameras, 37 thus reducing their costs and increasing potential adoption. A review by Panwar et al 38 described in detail several models of newer ophthalmic photography equipment, from small table-top models to smartphone-based options. These include the D-Eye system from Italy (D-Eye S.r.l, Padova, Italy) 39, 40 and the Ocular CellScope (Cellscope Inc, San Francisco, CA) from the United States. 41 
Perimetry
Full-threshold automated perimetry (eg, Humphrey, Octopus) is routinely used to confirm diagnosis of glaucoma and monitor disease progression. Alternatives to clinic-based standard automated perimetry have been developed, often to facilitate home monitoring. Smartphones and tablets have shown to be suited for vision testing, and they can communicate with other wireless platforms sending data automatically for analysis. 5 Although there are substantial challenges associated with home tonometry, including the calibration of monitors (eg, securing a constant illumination intensity and size of the stimuli), determining reliability of the test, and maintaining participant concentration, at the moment it is possible to perform VF tests using a tablet-based procedure. 3, 42 Tablets gather multiple suitable characteristics that make them ideal for portable low-cost perimetry, such as ubiquity, high spatial resolution, and large dynamic luminance range. 42, 43 Using a suprathreshold strategy, they are ideally suited for case detection in remote and underprivileged settings.
In addition to the role for detecting glaucoma, new perimetry technologies using tablets or portable computers have been layer were probably more accurate than macular measurements. 32 Due to the high proportion of retinal ganglion cell bodies and axons concentrated in the macula, macular parameters continue to receive attention as potential biomarkers in the detection of glaucoma, and improved technology has led to better retinal segmentation and potential increasing value to diagnose glaucoma.
The advent of digital photography has made it easier and cheaper to acquire and process optic disc images. Nonmydriatic stereoscopic cameras are particularly useful to evaluate the optic disc (Fig. 4) and help detect disease progression. Using image processing, relevant features, such as the optic disc and blood vessels, can be analyzed and provide useful information. 33 Advanced mobile phone technologies are enabling remote health care delivery and have been proposed as useful tools in glaucoma detection. Newer smartphone devices have highpowered computational functions, cameras, image processing, 
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Rodriguez-Una and Azuara-Blanco in combination with other tests, such as imaging using portable nonmydriatic fundus photography and tonometry. Cambridge Consultants has developed a smartphone glaucoma screening technology called Viewi that could be used in a clinic setting or from patients' homes. The Viewi system includes a smartphone app, a Bluetooth finger button, and a headset that holds smartphones. The smartphone is slid into the viewer, the app is started, and the patient can hold the button in 1 hand, pushing when a light flash is seen. The app runs a suprathreshold static perimetry test. 45 The test results are displayed in an intuitive format on the smartphone and can be shared instantly with health care professionals.
The Moorfields Motion Displacement Test (MMDT) is a novel accessible multilocation perimetry that can be presented on a laptop computer. It consists of a Windows-based software program. The MMDT uses the enhanced suprathreshold algorithm ESTA, which takes 90-120 seconds per eye. At a test distance of 30 cm, it presents 31 lines of stimuli in a location format that fits a 15-inch laptop screen. Each location corresponds to a location on the Humphrey 24-2 program.
This platform has shown good diagnostic performance for glaucoma; thus, it could be considered a further glaucoma diagnostic or screening tool. 46 It has been involved in several telemedicine projects, including those LMIC in Africa and in the Caribbean. 47 designed to facilitate patients performing unsupervised perimetric tests as part of a home-monitoring program. Similar strategies have been tried successfully in patients with age-related macular degeneration, and with promising results. 44 Vingrys et al 42 developed the Melbourne Rapid Fields (MRF) as a tangent perimeter on an iPad platform (Apple Inc, Cupertino, CA) with the aim of sampling central and peripheral VF using fast thresholding methods (Fig. 5) . The MRF can detect shallow simulated scotomas, with an approximate test duration of 4 minutes, and can potentially be used for detecting disease progression (https:// www.thinkable.org/groups/melbourne-rapid-fields-group).
The glaucoma screening application called Visual Fields Easy (VFE) is available for the iPad and can be downloaded for free. The VFE showed promising capacity compared with diagnosis based on a Humphrey 24-2 SITA-Standard outcome. The VFE test evaluates 96 test locations (24 per VF quadrant) across the central 30-degree radius in 3 minutes on average, and the testing distance is 33 cm. The results of the test can be directly printed or emailed using Wi-Fi from the iPad.
Johnson et al 3 evaluated the performance of the VFE screening procedure on an iPad for diagnosing glaucoma in a clinicbased study in Nepal and compared the results with the 24-2 SITA Standard test on the Humphrey Field Analyzer (Carl Zeiss Meditec Inc, Dublin, CA). They found that VFE worked well for identifying moderate-to-severe disease.
Before performing the VFE test the iPad requires calibration and we recommend performing tablet-based VF tests in a dimly lit room to avoid reflections. This procedure can be done
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Electrophysiology
Interruptions of the transmission of electrical pulses from the retinal ganglion cells through the visual pathway in people with glaucoma can be detected using visual evoked potentials (VEPs). 48 Recent improvements to VEP technology have increased its potential as a diagnostic tool for clinical use. This provides an objective means of testing glaucoma patients for visual function damage in comparison with the subjective standard automated perimetry. 49, 50 Specifically, short-duration transient VEP is based on a conventional pattern-reversal technique and has shown promise in detecting glaucoma. 51, 52 Nakanishi et al 53 developed the nGoggle system (nGoggle Inc, San Diego, CA), a new portable method to objectively assess VF loss in glaucoma based on multifocal steady-state VEP. This platform integrates wearable, wireless, dry electroencephalogram and electro-oculogram systems and a head-mounted display that can monitor the electrical brain activity associated with VF stimulation. Their study suggested that the nGoggle discriminated glaucomatous eyes from healthy ones. The promising performance in terms of glaucoma diagnosis needs to be confirmed with further studies. The possibility of using this test for monitoring of progressive glaucomatous change needs to be validated. The portability and objectivity of this device make it a promising tool for remote and home-based assessment of visual function in developed countries, although it is less attractive for LMIC settings.
MODELS OF GLAUCOMA CARE
Undoubtedly, one of the most important applications of new technologies in the field of eye care is the development of telemedicine. This concept refers to the practice of medicine at a spatial or temporal distance by exchanging medical information via electronic communications. 7 The adoption of telemedicine in ophthalmology is propitious as it is relatively easy to evaluate most eye diseases with the help of high-quality images.
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Important recent advances, such as improvement of wireless infrastructure, the role of smartphone technologies mentioned above, or the existence of better portable retinal imaging systems, will probably accelerate the use of mobile-enabled health systems and services throughout the world. Some prototypes and commercially available devices have already been explained elsewhere in this review. Moreover, Russo et al 39 discusses a possible future wholly smartphone-based teleophthalmology system, well supported by telemedicine networks, robust cloud storage systems, and secure encryption technology.
Remote glaucoma diagnosis is thus becoming a reality. An accurate teleglaucoma examination ideally requires optic nerve photographs, IOP measurements, and VF test. 55 Outputs from imaging glaucoma tests, including OCT, can generate digital data that can be transferred electronically and viewed remotely. 7 Several teleglaucoma care programs have been reported around the world, with particular attention in remote communities where there is a lack of specific glaucoma expertise, for examples:
1. An internet-based teleophthalmology system based on compressed stereoscopic digital photography was able to correctly and reliably identify patients requiring referral for glaucoma. 56 Previous similar experiences with diabetic retinopathy patients have been reported. 57 2. A Japanese group was successful in acquiring images using a remote-controlled slit lamp from glaucoma patients after filtrating surgery. 54 This system was provided with a robust digital video transport platform and was connected by highspeed Internet to an ophthalmologist's unit, remotely operated by means of a joystick. 3. A well-established teleophthalmology software is the Secure Diagnostic Imaging, developed at the University of Alberta. This system allows compressed digital image transfer to a server, stereoscopic digital viewing, image manipulation, generation and sending of reports in PDF format, and so on. 55 Advantages of teleglaucoma programs include the following 58 
Artificial Intelligence
Artificial intelligence is the simulation of human intelligence processes by machines, especially computer systems. It works by combining large amounts of data with fast and intelligent algorithms. An ANN is an information processing unit that is inspired by the way the human brain processes information. It consists of a large number of highly interconnected units (like neurons), suitably trained and working together to solve specific tasks. 33 The application of AI has been effective in the prediction of diseases. Several AI algorithms have been developed for screening, risk stratification, and assisted decision-making in disease prevention and treatment. 60 Strategies using AI have shown to be particularly useful in the building of guidelines and protocols. In addition, an interesting alternative use of AI is in the improvement of efficiency and cost-effectiveness of the medical process. 61 An example of AI technology is machine vision. Machine vision captures, analyzes, and interprets visual information from a picture or video using a camera and digital signal processing and can be used in medical image analysis. In the field of ophthalmology, previous experiences with ANN for diagnosis and treatment of congenital cataracts have been reported. 60 The idea of using ANN and other AI strategies as glaucoma diagnostic tools is becoming a reality. In fact, several techniques have been used 33 Moorfields Eye Hospital's collaboration with Google (Alphabet Inc, Mountain View, CA) DeepMind aims to create a general purpose AI algorithm that can look at OCT scans and diagnose age-related macular degeneration and diabetic retinopathy. 62 The company VISULYTIX has recently introduced PEGASUS (Visulytix Ltd), a new deep learning-based AI technology. 63 It consists of an inexpensive smartphone clip-on optic nerve scanner that looks at a number of features within fundus images and provides information about the health of the optic disc. PEGASUS can be used not only for glaucoma detection but also for diabetic retinopathy and macular diseases. 64 It has been highlighted that data from different source domains have a complementary effect in boosting glaucoma diagnosis. As data heterogeneity is inevitable in clinical practice, the management of multisource and wide-format data is essential. Some reported examples of possible combinations of tests using AI are as follows: Table 1 is the summary of applications of new technologies for glaucoma detection mentioned above.
Genetic Testing
We have observed an increasing number of genetic studies in glaucoma in the recent past, mainly due to a substantial reduction in the cost of high-throughput genome-wide genotyping platforms. In glaucoma it seems that genetic testing may be helpful in some circumstances, such as screening of family members in OAG affecting young people with an apparent autosomal dominant inheritance. It has been proposed that genetic testing may help predict conversion from ocular hypertension to glaucoma or help predict disease progression, but validation of these observations is required. A number of international collaborations are currently ongoing, trying to better understand the genetic components of glaucoma. However, at the moment genetic testing of wider populations is not justified. 68 
Big Data
The expansion of the Internet, along with the development of innovative technologies, has increased the use of large-scale data, or "big data," in recent years. An interesting application in the field of ophthalmology is to pool large databases together to identify trends and also predict future risks to vision. Regarding glaucoma, Jones et al 69 assessed whether big data analysis could be used to identify patients achieving VF test scores outside of the expected range. By using big data, they showed that the newly designed model of service delivery resulted in equivalent outcomes to that of the standard outpatient model for the studied VF parameters.
Design and Reporting of Diagnostic Studies in Glaucoma
Unfortunately, there are deficiencies in the design and reporting of studies of diagnostic tests in general and glaucoma in particular. 70, 71 A case-control study in which a novel diagnostic test is applied to a group of patients with the condition (eg, glaucoma) and a group of normal controls is associated with a high risk of bias but still commonly used. 72 Important aspects of study methods are often omitted or poorly described, making critical appraisal difficult. For example, if not all patients receiving the test are included in the final analysis (eg, excluding those with poor-quality testing) important information about the performance of the technology in real life will be missing. A greater effort is needed to improve the methodological and reporting standards of diagnostic accuracy studies in glaucoma.
CONCLUSIONS
New technologies for glaucoma detection have emerged but their potential value and adoption greatly depends on the setting and the potential use of the test. Current clinical diagnosis based on face-to-face expert examination of the optic disc supplemented by OCT and VF testing with automated perimetry is not possible or feasible in developing countries and remote locations. Possible adoption of teleglaucoma and portable tablet or smartphone-based technologies is expected to facilitate glaucoma detection and management in remote and underserved populations. A greater effort is needed to improve the quality of diagnostic accuracy studies in glaucoma.
